Human Oncology & Pathogenesis Program

Our teams of physician-scientists are working to translate molecular insights into new treatments for cancer.

Learn more »
As a member of HOPP, Ingo Mellinghoff cares for patients with brain cancer and also leads a laboratory focused on understanding the genetic causes of brain tumors.
Pictured: Ingo Mellinghoff

Browse our lab heads

Select...

HOPP Year in Review

One of the goals of the Human Oncology and Pathogenesis Program (HOPP) is to achieve progress in various areas of cancer research. In our 2011 Year in Review, learn about our collaborations, innovations, and training that have had an impact on Memorial Sloan-Kettering and its patients.

View report »

Pictured: Charles Sawyers
Research Suggests a New Approach for Overcoming Resistance to a Targeted Therapy for Prostate Cancer

Research suggests that a new drug could be effective in patients with prostate cancer who develop resistance to the targeted therapy enzalutamide.

Pictured: Charles Sawyers
Pictured: James Fagin
Drug Reverses Radioiodine Resistance in Some People with Advanced Thyroid Cancer

Researchers have found that the investigational drug selumetinib shuts down the signaling of genetic mutations that prevent some patients’ thyroid cancer tumors from absorbing radioiodine, the most effective treatment for the disease.

Pictured: James Fagin
Pictured: PET Scan
New Imaging Agent Could Improve Prostate Cancer Diagnosis and Treatment

Researchers at Memorial Sloan-Kettering are developing a new strategy for PET imaging of tumors that could result in new tools to detect and monitor prostate cancer.

Pictured: PET Scan
Pictured: Marc Ladanyi & Snjezana Dogan
Study Suggests Women Are More Susceptible to Smoking-Related Lung Cancers

A genetic analysis of tumors suggests women are more susceptible than men to the most common form of lung cancer.

Pictured: Marc Ladanyi & Snjezana Dogan